Search

Displaying results 761 - 770 of 1786 in total
  1. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.

  2. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.

  3. Drug

    Iopromide

    go.drugbank.com/drugs/DB09156
    Approved

    [A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction

  4. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    [A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929] … monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus erythematosus, but so far

  5. Drug

    Hydrocortisone

    go.drugbank.com/drugs/DB00741
    ApprovedInvestigationalVet approved

    [A188420] Hydrocortisone was granted FDA approval on 5 August 1952.[L10574]

  6. Drug

    Testosterone cypionate

    go.drugbank.com/drugs/DB13943
    ApprovedInvestigational

    It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.

  7. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    [A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]

  8. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

  9. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    as treatments for retinal diseases; Enzeevi (aflibercept-abzv)[L53053], approved in August 2024, was also approved by the FDA for similar indications. … [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in

  10. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).